NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Navinci Diagnostics

Navinci Diagnostics

Private
UppsalaHealthcare & Life Scienceshttps://navinci.se/

Last Round

Early Funding

Jun 25, 2025

Total Funding Raised

$14.66M

Company Overview

Navinci Diagnostics is a biotechnology company that develops and markets in situ proximity ligation assays to detect proteins, their interactions, and modifications in tissue and cell samples.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

spatial proteomicsin situ Proximity Ligation AssayisPLAprotein interaction analysisspatial biologyassay kitslife science toolsPTM detectionin situ analysismultiplex assaybiomarker discoveryimmuno-oncologydrug developmentspatial interactomicsneurosciencepathology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Navinci Diagnostics Comparables

Compare Navinci Diagnostics with similar companies based on industry and business-model similarity.

Navinci Diagnostics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pixelgen Technologies
81%
Bio-Techne Corporation
76%
Vizgen
76%

Navinci Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJun 25, 2025
Series AJul 12, 2022

Key People

Founding team and executive leadership

Jenny Sundqvist

Chief Executive Officer

Executive Team

Magnus Hurst

CFO

Executive Team

Navinci Diagnostics Investors

Notable investors and investment history

Navinci Diagnostics investors
InvestorRounds
Meltwind AdvisoryEarly Funding
Segulah Medical AccelerationEarly Funding, Series A
NXT2BSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 22, 2026

    Monthly visitors increased 60% MoM.

  • Jun 25, 2025

    Raised $6.15M from Segulah Medical Acceleration and others.

Navinci Diagnostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Navinci Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Navinci Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersUppsala
Employee Range30
Year Founded2004
Last FundingJun 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.